(via NewsDirect)
Barder also gives an update on the company's discussions with the FDA regarding MED3000, saying that he expects approval to come during the second quarter.
Contact Details
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source